Amgen, already on PCSK9 offense, slaps Sanofi, Regeneron with Dupixent patent suit

Fierce Pharma -------- Last month, Sanofi and Regeneron sued Amgen in a move to fend off a nasty patent court battle over their new atopic dermatitis drug Dupixent. After all, the two companies were already fighting Amgen to keep their PCSK9 cholesterol-fighter Praluent on the market. Amgen has since sued back—but its new complaint suggests this legal fight will be different from the bruising PCSK9 case, which is now under review by a federal appeals court. Amgen threw down its own legal gauntlet—somewhat covertly—by suing Sanofi and Regeneron for patent infringement in California earlier this month, under the auspices of Immunex, its patent-owning subsidiary. To learn more click on the picture below to read the article.